Difference between revisions of "Profiles"
Jump to navigation
Jump to search
Line 5: | Line 5: | ||
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles=== | ===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles=== | ||
+ | |||
+ | * [[Media:QIBA_CTVol_TumorVolumeChangeProfile_TechConfirmed-20180622.pdf|CT Tumor Volume Change for Advanced Disease (CTV-AD) 2018-06-22]] | ||
+ | |||
+ | |||
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]] | * [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]] | ||
:* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 Dec-2014]] | :* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 Dec-2014]] |
Revision as of 15:59, 6 July 2018
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Profiles may be of use at any Stage.
Stage 3: Technically Confirmed Profiles
Stage 2: Consensus Profiles
Stage 1: Public Comment Profiles
Submit comments using the online form: http://tinyurl.com/QIBA-Public-Comment-Form
(Note: each form accommodates 10 comments; submit additional forms as necessary)
- There are currently no Profiles open for Public Comment
Public Comment closed for the following Profiles (comment resolution is underway on the corresponding committee page):
- fMRI 2017-06-19 (Closed on December 31, 2017)
- PET Amyloid: 18F-labeled PET Tracers Targeting Amyloid as an Imaging Biomarker - 2018-05-02 (Closed on September 15, 2017)
- MR Elastography 2017-08-15 (Closed on September 15, 2017)
- MR DWI 2017-04-27 (Closed on August 25, 2017)
Format for Citing Profiles
Cite QIBA Profile documents as:
- Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. QIBA, Date. Available from: URL
Example:
- QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1. Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)